Comunicados de prensa

25 ene. 2018

Synthon’s [vic-]trastuzumab duocarmazine (SYD985) granted FDA Fast Track designation for pre-treated HER2-positive metastatic breast cancer 2

read more
05 oct. 2017

Regulatory Approval in Europe granted for Synthon’s glatiramer acetate 40 mg/ml

read more
13 sept. 2017

European Patent Office decides in Synthon’s favor in glatiramer patent case

read more
15 mar. 2017

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

read more
02 mar. 2017

Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway

read more
12 dic. 2016

MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC

read more
18 may. 2016

Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients

read more
12 abr. 2016

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

read more
28 sept. 2015

Synthon Reports Promising Initial Results from Phase I Trial with anti-HER2 ADC SYD985

read more
03 ago. 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

read more